Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: secondary leukemia + novantrone + cardiotoxicity  Related to the article below (Last Update: 7/8/2008)

Business Card & Bone Marrow Drive
KVBC, NV -
Brandon's quest for a world record is secondary to his drive to beat leukemia. He's looking for a bone marrow donor match and you can help by registering to ...
Quinamed? + ARA-C Effective for Secondary Acute Myeloid Leukemia
Cancer Consultants, ID - Jun 17, 2008
... Quinamed? (amonafide, benzisoquinolinedione, nafidimide) and ara-C is active in the treatment of patients with secondary acute myeloid leukemia (sAML). ...

South Delta Leader
WEB EXTRA-Sign of disrespect?
South Delta Leader, Canada -
Opponents of the project are concerned health issues such as childhood leukemia are linked to the electromagnetic radiation and want the lines buried. ...
UPDATE-Playful protest South Delta Leader
all 5 news articles »
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 ...
FOXBusiness - Jul 1, 2008
Over time, MDS can progress to acute myelogenous leukemia (AML). The Aplastic Anemia and MDS International Foundation currently estimates that up to 30000 ...SUPG - OTC:CMTX
Focus on the World Chitin & Chitosan Market
Market Wire (press release) - Jul 7, 2008
... Formation II-30 Other Industries Using Chitin II-30 Potential Applications of Chitin and Chitosan II-30 Treatment of Tumors and Leukemia II-30 Medical ...

Vancouver Sun
Tsawwassen prepares for summer of protest
Vancouver Sun,  Canada - Jul 5, 2008
A 2005 paper in the peer-reviewed British Medical Journal concludes: "There is an association between childhood leukemia and proximity of home address at ...
Hawken grad Alex Dobay can teach us all something
The Plain Dealer - cleveland.com, OH - Jun 9, 2008
He, Alex - who had beaten two bouts of non-Hodgkins lymphoblastic lymphoma and is now battling a secondary leukemia - graduated. "It was incredible," said ...

Ottawa Citizen
Lyle a winner on PGA Tour circuit
The Age, Australia - Jun 23, 2008
Lyle, who had leukemia as a child, admits he got carried away by the hype after he made it on to the US PGA Tour for the first time last year. ...
Lyle a stroke away from big time Sydney Morning Herald
all 123 news articles »
Cytokinetics Announces Clinical Data Regarding Ispinesib in ...
FOXBusiness - Jun 30, 2008
The secondary objective was to assess the clinical activity of this combination in patients with advanced solid tumors. Although a single dose regimen was ...CYTK - CLDA - OTC:CMTX
Prospect reports positive interim results from Phase II leukemia trial
Pharmaceutical Business Review - Jun 9, 2008
The secondary objective of the study is to evaluate the effect of GCS-100 on peripheral blood leukocyte counts, which are aberrantly elevated in CLL ...
Source: Google News

Increased Risk of Acute Leukemia After Adjuvant Chemotherapy for Breast Cancer: A Population-Based … -
G Chaplain, C Milan, C Sgro, PM Carli, C Bonithon- … - Journal of Clinical Oncology, 2000 - jcojournal.org
... and DW Paty The use of mitoxantrone (Novantrone) for the ... Socie, and G. Rosti Low
incidence of secondary myelodysplasia and acute myeloid leukemia after high ...

Novantrone Linked to Cardiotoxicity and AML in MS and Cancer Patients
Y Waknine - medscape.com
... risks of cardiotoxicity and secondary acute myelogenous leukemia (AML) associated
with use of mitoxantrone for injection concentrate (Novantrone) in patients ...

FDA Safety Labeling Changes: Novantrone, Mevacor, Nitro-Dur -
Y Waknine, LMMCL Dysfunction - mp.medscape.com
... for mitoxantrone injection (Novantrone, made by Serono Inc.) to warn of the risks
of cardiotoxicity and secondary acute myelogenous leukemia (AML) associated ...
-

NOVANTRONE? -
G ADVERSE REACTIONS - 216.86.213.73
... ADMINISTRATION. Secondary acute myelogenous leukemia (AML) has been reported in
cancer patients ... NOVANTRONE is an anthracenedione, a related drug. The ...
-

Mitoxantrone in secondary progressive multiple sclerosis: a review of toxicity in 41 patients -
S Peak, DD Tsao-Wei, MC Chamberlain - Therapy, 2007 - Future Medicine
... Mitoxantrone (Novantrone ? ; Immunex) is an immunosuppressive agent approved for
treatment of secondary progressive multiple ... of treatment-related leukemia [8,9 ...

Mitoxantrone (Novantrone?) in multiple sclerosis: new insights -
O Neuhaus, BC Kieseier, HP Hartung - ern, 2004 - Future Drugs
... loss is a (patho-) physiological secondary response to ... approval of mitox- antrone
(Novantrone ? , AstraZeneca, London ... prostate cancer, lymphoma and leukemia [24 ...

Troubleshooting Mitoxantrone Use in MS: Combo Therapy May Be Way to Go
T RISKS - psychiatrictimes.com
... The addition of mitoxantrone (Novantrone) to interferon ... been reached, risk of leukemia
and cardiotoxicity ... the treatment of secondary progressive, progressive ...
-

… acute leukemia AML and analysis of prognostic factors: Results of the EORTC Children Leukemia … -
C Behar, S Suciu, Y Benoit, A Robert, E Vilmer, P … - Medical and Pediatric Oncology, 1996 - doi.wiley.com
... its cardiotoxicity limits the total cumulative dose which can safely be given. ... years
of age with newly diag- nosed AML, excluding secondary leukemia, were regis ...

Mitoxantrone in the treatment of relapsed and refractory acute leukemia -
P Meyer, AD Ho, G Ehninger, I Mjaaland, E … - Investigational New Drugs, 1985 - Springer
... Mitoxantrone (Novantrone| dihydroxyanthra- cenedione) is a synthetic ... refrac- tory
relapsed leukemia, primary treatment of ... CR<6 months), secondary treatment of ...

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis Report of the … -
DS Goodin, BG Arnason, PK Coyle, EM Frohman, DW … - Neurology, 2003 - AAN Enterprises
... Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients ...
Leukemia . ... Study Group on Interferon ?-1b in Secondary Progressive MS. ...

Source: Google Scholar
 
 

Novantrone, cardiotoxicity and secondary leukemia

 
 
Serono sent to healthcare professionals a supplement information concerning the risks of cardiotoxicity associated with Novantrone ( Mitoxantrone for injection concentrate ) treatment for multiple sclerosis ( MS ) and also provides supplemental information regarding secondary acute myelogenous leukemia ( AML ) reported in multiple sclerosis patients treated with Novantrone
Reports received through post-marketing surveillance, have shown that diminished cardiac function may occur early on in the treatment with Novantrone.

Therefore, the Product Labeling for Novantrone was updated in March 2005 to state that cardiac monitoring of MS patients should be performed at baseline and prior to administration of every dose of Novantrone.

Novantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary ( chronic ) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis ( i.e., patients whose neurologic status is significantly abnormal between relapses ). Novantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis.

Use of Novantrone has been associated with cardiotoxicity.
Cardiotoxicity can occur at any time during Novantrone therapy, and the risk increases with cumulative dose. Congestive heart failure ( CHF ), potentially fatal, may occur either during therapy with Novantrone or months to years after termination of therapy. All patients should be carefully assessed for cardiac signs and symptoms by history and physical examination prior to start of Novantrone therapy.
Baseline evaluation of left ventricular ejection fraction ( LVEF ) by echocardiogram or multi-gated radionuclide angiography ( MUGA ) should be performed.
Multiple sclerosis patients with a baseline LVEF <50% should not be treated with Novantrone.
LVEF should be reevaluated by echocardiogram or MUGA prior to each dose administered to patients with multiple sclerosis.

Additional doses of Novantrone should not be administered to multiple sclerosis patients who have experienced either a drop in LVEF to below 50% or a clinically significant reduction in LVEF during Novantrone therapy. Patients with multiple sclerosis should not receive a cumulative dose greater than 140mg/m2.

In cancer patients, the risk of symptomatic congestive heart failure ( CHF ) was estimated to be 2.6% for patients receiving up to a cumulative dose of 140mg/m2.

Presence or history of cardiovascular disease, prior or concomitant radiotherapy to the mediastinal / pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs may increase the risk of cardiac toxicity. Cardiac toxicity with Novantrone may occur whether or not cardiac risk factors are present.

Secondary acute myelogenous leukemia ( AML ) has been reported in multiple sclerosis and cancer patients treated with Mitoxantrone. In a cohort of Mitoxantrone treated MS patients followed for varying periods of time, an elevated leukemia risk of 0.25% ( 2/802 ) has been observed. postmarketing cases of secondary AML have also been reported.
In 1774 patients with breast cancer who received Novantrone concomitantly with other cytotoxic agents and radiotherapy, the cumulative risk of developing treatment-related AML, was estimated as 1.1% and 1.6% at 5 and 10 years, respectively.
Secondary acute myelogeneous leukemia ( AML ) has been reported in cancer patients treated with anthracyclines.
Novantrone is an anthracenedione, a related drug.
The occurrence of refractory secondary leukemia is more common when anthracyclines are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated.

Cases of secondary AML in multiple sclerosis patients treated with Novantrone have been reported in peer-reviewed literature, through the collection of spontaneous reports, and in a prospective observational study.
Because the number of multiple sclerosis patients exposed to Novantrone in post-marketing is unknown and because spontaneous reporting of adverse events can be subject to under-reporting, it is not possible to determine incidence—or relative risk to an MS patient—of developing secondary AML.

Effects in Worsening MS ( RENEW ) is an ongoing 5-year, post-marketing, observational study involving a cohort of 505 patients with worsening relapsing-remitting, secondary progressive, or progressive-relapsing MS.
Since initiation of patient enrollment in April 2001, there has been one case of secondary AML reported, involving a 52-year-old female with secondary progressive multiple sclerosis.
She had received a cumulative total of 72 mg/m2 of Novantrone, in six infusions given from August 2001 to December 2002, when she was noted to be neutropenic, at which time her treatment with Novantrone was stopped.
In May 2004, she was noted to have peripheral blasts and bone marrow biopsy confirmed AML.
This patient had no other known risk factors for leukemia and no concomitant potentially cytotoxic drugs were listed.
Her AML was considered probably related to Novantrone.
Since treatment with Idarubicin and Ara-C, she has been in remission.
Based on this case, the incidence rate in this study is increased as compared to a non-exposed matched population.
Because of the risk of secondary AML, strict adherence to existing blood cell count monitoring recommendations for patients being treated with Novantrone for MS should be followed with complete blood counts, including platelets, prior to each course of Novantrone and in the event that signs or symptoms of infection develop.

Novantrone generally should not be administered to MS patients with neutrophil counts less than 1500 cells/mm3.
Also, regular blood cell counts should be monitored after discontinuation of Novantrone therapy.

Source: FDA, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;

 

ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page